The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Meta-analysis of three trials found that immediate breast surgery in women over 70 cut breast cancer death rates in half ...

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Interim overall survival (OS) analyses at 31% maturity in patients with ESR1 mutations, and 23% maturity among all patients, ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...

The company found that the 1 mg dose of Z-endoxifen reduced MBD by 17.3 percentage points, whereas the 2 mg dose achieved a reduction of 23.5 percentage points. Meanwhile, a minimal change of 0.27 ...

Atossa Therapeutics (ATOS) announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska Institute in Stockholm, ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...